Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - License Agreements - Additional Information (Details)

v3.21.2
Commitments and Contingencies - License Agreements - Additional Information (Details) - TMRC - USD ($)
$ in Millions
1 Months Ended 9 Months Ended
Sep. 30, 2021
May 31, 2021
Sep. 30, 2016
May 31, 2016
Sep. 30, 2015
Sep. 30, 2021
Sep. 30, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Up-front license fee         $ 1.0    
Payment of up-front license fee       $ 0.5 0.5    
Payments per indication due upon the successful achievement of clinical and regulatory milestones         $ 13.0    
Payments made upon achievement of development milestone $ 1.0 $ 2.0 $ 1.0        
Fees incurred under supply management agreement           $ 0.6 $ 0.8